Open Access

Preparation and characterization of the Adriamycin‑loaded amphiphilic chitosan nanoparticles and their application in the treatment of liver cancer

  • Authors:
    • Chang‑Hua Kou
    • Jin Han
    • Xi‑Lin Han
    • Hui‑Jie Zhuang
    • Zi‑Ming Zhao
  • View Affiliations

  • Published online on: October 18, 2017     https://doi.org/10.3892/ol.2017.7210
  • Pages: 7833-7841
  • Copyright: © Kou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the present study, two nanoparticles including lactose myristoyl carboxymethyl chitosan (LMCC) and algal polysaccharide myristoyl carboxymethyl chitosan (AMCC), were obtained for hepatic‑targeted Adriamycin (ADM) drug delivery systems. ADM was successfully loaded into the LMCC or AMCC nanoparticle by dialysis. The release function and liver targeting of the nanoparticles was explored, and it was revealed that ADM release from the nanoparticles was greatest at acidic pH 5.5. ADM‑conjugated nanoparticles were readily taken up by HU7 human hepatocellular carcinoma cells, relative to HT22 mouse hippocampal neuron cells in vitro. In vivo, ADM‑loaded nanoparticles had significant antitumor efficacy with a 62.7% inhibition rate, followed by ADM and ADM‑AMCC (51.2 and 42.5%, respectively). The tissue distribution study confirmed that ADM‑LMCC had an improved liver delivery efficacy, by comparison with ADM. Furthermore, a series of safety studies, including hemolysis, acute toxicity and organ toxicity, revealed that the ADM‑loaded LMCC and AMCC nanoparticles had advantages over the commercially available injectable preparation of Adriamycin hydrochloride, in terms of low toxicity levels and increased tolerated dose. These results indicated that LMCC is a promising carrier for injectable ADM nanoparticle and ADM‑conjugated nanoparticles may improve the efficacy of ADM by hepatic targeting.
View Figures
View References

Related Articles

Journal Cover

December-2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kou CH, Han J, Han XL, Zhuang HJ and Zhao ZM: Preparation and characterization of the Adriamycin‑loaded amphiphilic chitosan nanoparticles and their application in the treatment of liver cancer. Oncol Lett 14: 7833-7841, 2017.
APA
Kou, C., Han, J., Han, X., Zhuang, H., & Zhao, Z. (2017). Preparation and characterization of the Adriamycin‑loaded amphiphilic chitosan nanoparticles and their application in the treatment of liver cancer. Oncology Letters, 14, 7833-7841. https://doi.org/10.3892/ol.2017.7210
MLA
Kou, C., Han, J., Han, X., Zhuang, H., Zhao, Z."Preparation and characterization of the Adriamycin‑loaded amphiphilic chitosan nanoparticles and their application in the treatment of liver cancer". Oncology Letters 14.6 (2017): 7833-7841.
Chicago
Kou, C., Han, J., Han, X., Zhuang, H., Zhao, Z."Preparation and characterization of the Adriamycin‑loaded amphiphilic chitosan nanoparticles and their application in the treatment of liver cancer". Oncology Letters 14, no. 6 (2017): 7833-7841. https://doi.org/10.3892/ol.2017.7210